Resumen de acción 1093 N CSPC Pharmaceutical Group Limited, un holding de inversiones, se dedica a la investigación y desarrollo, fabricación y venta de productos farmacéuticos en la República Popular China, otras regiones asiáticas, América, Europa y a escala internacional. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Añadir notaCompetidores de CSPC Pharmaceutical Group Limited Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del CSPC Pharmaceutical Group Precios históricos de las acciones Precio actual de la acción HK$15.69 Máximo en las últimas 52 semanas HK$15.69 Mínimo de 52 semanas HK$15.69 Beta 0.71 Cambio en 1 mes 0% Variación en 3 meses n/a Cambio de 1 año -27.02% Variación en 3 años n/a Variación en 5 años n/a Variación desde la OPV -41.10%
Noticias y actualizaciones recientes CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06 CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA
CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval Sep 20
CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares. Sep 19 Ver más actualizaciones CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06 CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA
CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval Sep 20
CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares. Sep 19 CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024 Aug 21
CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jul 11 CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval
CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 25 CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023
CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China May 18
CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024 May 16
Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs May 15
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023 Apr 28
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S Apr 27
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval Mar 23 CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024 Mar 20
CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration Jan 15
CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA Dec 18
CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets Dec 12
CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China Dec 02
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 29
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 28
CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023 Nov 21
CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China Nov 18
New major risk - Earnings quality Nov 16
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE Nov 08
CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China Nov 04
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Oct 31
CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors Oct 26
CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA Sep 07
CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval Aug 30
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 25
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023 Aug 24
CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 12
Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161) Jun 30
CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Jun 27 CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China
Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301 Jun 09
Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China Jun 07
Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023 Jun 06
CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022 Jun 01
CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023 May 17
Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.47 in FY 2021) Mar 23
CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval Jan 05
Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval Dec 31
CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 30
CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S Dec 23 Cspc Pharmaceutical Group Limited Announces That Syh2055 Developed by the Group Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 08
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate CPO204 Obtains Clinical Trial Approval in the U.S Nov 30
Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 3Q 2021) Nov 24
CSPC Pharmaceutical Group Limited's SYHX1901 Tablets Obtains Approval Granted by the National Medical Products Administration Nov 24
CSPC Pharmaceutical Group Limited Announces New Indication Application for Marketing Approval of Mingfule Nov 17
CSPC Pharmaceutical Group Limited to Report Nine Months, 2022 Results on Nov 23, 2022 Nov 12
CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director Nov 09
CSPC Pharmaceutical Group Limited Announces the Antibody-Drug Conjugate Sys6002 Oct 28
CSPC Pharmaceutical Group Limited Announces TG103 Injection Obtains Clinical Trial Approval for the Treatment of Non-Alcoholic Steatohepatitis Sep 10
Upcoming dividend of HK$0.10 per share Sep 01
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on 11 October 2022 Aug 25
Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 2Q 2021) Aug 24
CSPC Pharmaceutical Group Limited Announces Completion of Clinical Study of Heterologous Booster Immunization of SARS-CoV-2 mRNA Vaccine Aug 24
Cspc Pharmaceutical Group Limited Announces Selective Ntrk and Ros1 Dual Inhibitor Syhx2009 Obtains Clinical Trial Approval Aug 23
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 20
Cspc Pharmaceutical Group Limited Obtains Duoenda (Mitoxantrone Hydrochloride Liposome Injection) Clinical Trial Approval for the Treatment of Neuromyelitis Optica Spectrum Disorders Aug 19
CSPC Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 24, 2022 Aug 13
CSPC Pharmaceutical Group Announces Resignation of Wu Guizhen as Independent Non-Executive Director Aug 02
CSPC Pharmaceutical Group Limited Announce Biologic License Application for Jmt103 Accepted by the NMPA Jun 23
First quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 1Q 2021) May 31 Rentabilidad de los accionistas 1093 N MX Pharmaceuticals Mercado MX 7D 0% 4.3% -2.4% 1Y -27.0% -26.1% -14.9%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: 1093 N igualó a la industria MX Pharmaceuticals, que obtuvo un rendimiento del -26.1% el año pasado.
Rentabilidad vs. Mercado: 1093 N obtuvo unos resultados inferiores a los del mercado MX, que fueron del -14.9% el año pasado.
Volatilidad de los precios Is 1093 N's price volatile compared to industry and market? 1093 N volatility 1093 N Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.6% Market Average Movement 4.1% 10% most volatile stocks in MX Market 6.0% 10% least volatile stocks in MX Market 2.7%
Precio estable de las acciones: 1093 N no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 1093 N en el último año.
Acerca de la empresa CSPC Pharmaceutical Group Limited, un holding de inversiones, se dedica a la investigación y desarrollo, fabricación y venta de productos farmacéuticos en la República Popular China, otras regiones asiáticas, América, Europa y a escala internacional. La empresa opera a través de los segmentos de medicamentos acabados, productos a granel y alimentos funcionales y otros. Ofrece cápsulas blandas e inyecciones de NBP para el ictus isquémico agudo; cápsulas e inyecciones de Oulaining para tratar el deterioro mental y de la memoria de leve a moderado; Enxi para tratar la enfermedad de Parkinson idiopática del adulto; Duomeisu para el linfoma, el mieloma múltiple, los cánceres de ovario y mama y otros tumores malignos; Jinyouli para prevenir la leucopenia y la infección inducida por la quimioterapia; y Keaili para el cáncer de mama.
Mostrar más Resumen de fundamentos de CSPC Pharmaceutical Group Limited ¿Cómo se comparan los beneficios e ingresos de CSPC Pharmaceutical Group con su capitalización de mercado? Estadísticas fundamentales de 1093 N Capitalización bursátil Mex$151.69b Beneficios(TTM ) Mex$14.61b Ingresos (TTM ) Mex$74.74b
10.4x Ratio precio-beneficio (PE)
2.0x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de 1093 N Ingresos CN¥31.31b Coste de los ingresos CN¥9.34b Beneficio bruto CN¥21.97b Otros gastos CN¥15.85b Beneficios CN¥6.12b
Últimos beneficios comunicados
Sep 30, 2023
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) 0.52 Margen bruto 70.17% Margen de beneficio neto 19.54% Ratio deuda/patrimonio 1.2%
¿Cómo se ha desempeñado 1093 N a largo plazo?
Ver rendimiento histórico y comparativa Dividendos
4.7% Rentabilidad actual por dividendo
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/02/12 14:37 Precio de las acciones al final del día 2023/11/15 00:00 Beneficios 2023/09/30 Ingresos anuales 2022/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas CSPC Pharmaceutical Group Limited está cubierta por 50 analistas. 27 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Wai Chak Yuen BOCI Research Ltd. Sharon Shi BOCI Research Ltd. Ethan Cui BofA Global Research
Mostrar 47 más analistas